Baricitinib – 5 mg

Brand:
Cayman
CAS:
1187594-09-7
Storage:
-20
UN-No:
Non-Hazardous - /

Janus kinases (JAKs) are non-receptor kinases that mediate signaling through cytokine receptors, often to members of the signal transducer and activator of transcription (Stat) family.{20362} Baricitinib is an orally bioavailable, reversible inhibitor of JAK1 and JAK2 (IC50s = 5.9 and 5.7 nM, respectively) that has been shown to inhibit cytokine-induced phosphorylation of STAT3 in healthy human volunteers.{27359,27358,27357} It has potential application in various inflammatory disorders, including rheumatoid arthritis.{27359,27357}  

 

Out of stock

SKU: - Category:

Description

An orally bioavailable, reversible inhibitor of JAK1 and JAK2 (IC50s = 5.9 and 5.7 nM, respectively) that has been shown to inhibit cytokine-induced phosphorylation of STAT3 in healthy human volunteers


Formal name: 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile

Synonyms:  INCB 028050|LY3009104

Molecular weight: 371.4

CAS: 1187594-09-7

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|JAK Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Signaling|JAK Signaling||Research Area|Epigenetics, Transcription, & Translation|Transcription Factors